Recognizing and treating Mycobacterium avium complex pulmonary disease (MAC-PD)
Mycobacterium avium complex pulmonary disease (MAC-PD) is an increasingly recognized cause of chronic pulmonary infection, yet it remains frequently missed in clinical practice due to its nonspecific presentation and overlap with more common conditions. This clinical review summarizes the pathogenesis, risk factors, clinical presentation, diagnostic criteria, differential diagnosis, pharmacologic treatment, and supportive care of MAC-PD for advanced practice clinicians. Two clinical phenotypes are discussed: fibrocavitary disease, seen more often in older men with structural lung disease, and nodular bronchiectatic disease, seen more often in older women. Diagnosis requires meeting clinical, radiographic, and microbiologic criteria per the 2020 ATS/ERS/ESCMID/IDSA guideline. Treatment consists of a macrolide-based three-drug regimen guided by disease phenotype, severity, and drug susceptibility that is continued for at least 12 months after sputum culture conversion. Airway clearance therapy, nutritional support, and mitigation of environmental and other modifiable risk factors are integral to comprehensive management. Recognizing MAC-PD early and initiating appropriate treatment can prevent progressive lung damage and improve quality of life for affected patients.
Authors
- Zhi Peng Li
Publication Details
- Journal
- JAAPA
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1097/01.jaa.0000000000000438
- Primary Topic
- Mycobacterium research and diagnosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00